Cellectis to Present New Data Update on Its Allogeneic CAR T Cell Therapeutics at the 19th Congress of the European Hematology Association (EHA)

Dr. Julianne Smith, PhD, VP CART Development at Cellectis (Paris:ALCLS) and Dr. Roman Galetto, PhD, Project Leader, will be attending the 19th Congress of the European Hematology Association in Milan, Italy from June 12th to 15th, 2014.

Roman Galetto will present a study entitled: MULTIPLEX GENOME EDITING OF TCRALPHA/CD52 GENES AS A PLATFORM FOR "OFF THE SHELF” ADOPTIVE T-CELL IMMUNOTHERAPIES on the late breaker session to be held on Saturday, June 14^th at 1:30pm in the Auditorium (NW – Level 3).

Disruptive innovation in oncology by gene editing and T cell CARs

Cellectis is developing innovative cancer products based on engineered T cells armed with a Chimeric Antigen Receptor (CAR) to target liquid and solid tumors. Cellectis’ state-of-the-art genome engineering technologies together with the next generation of msCAR and an allogeneic cGMP manufacturing process for CART products take this new paradigm shift in oncology to the next level of the industry. The Company’s pipeline focuses on leukemia and solid tumors.

About Cellectis
Cellectis is a biopharmaceutical company focused on oncology. The company’s mission is to develop a novel generation of therapy based on engineered T-cells to treat cancer. Cellectis capitalizes on its 14 years of expertise in genome engineering, based on TALEN™, meganucleases and the state-of-the-art electroporation technology Pulse Agile, to create a new generation of cancer immunotherapy for treating leukemias and solid tumors. Cellectis adoptive cancer immunotherapy for chronic and acute leukemias is based on the first allogeneic T-cell chimeric antigen receptor (CAR) technology. CAR technologies are designed to target surface antigens expressed on cells. These treatments reduce toxicities associated with current chemotherapeutics and have the potential for curative therapy. The Cellectis Group is focused on life sciences and uses leading genome engineering technologies to build innovative products in various fields and markets. Cellectis is listed on the NYSE Alternext market (ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com.

Disclaimer
This news release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe for shares in Cellectis in any country. This news release contains forward-looking statements that relate to the Company’s objectives based on the current expectations and assumptions of the Company’s management only and involve unforeseeable risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements.